HIV and COVID-19: Drawing Lessons from Dual Pandemics

28 July 2022

Meg Doherty, MD, MPH, PhD
Director - Global HIV, Hepatitis and STIs Programmes
World Health Organization
COVID-19 Situation: COVID-19 is not over

Globally, as of 4:28pm CEST, 27 July 2022, there have been 570,005,017 confirmed cases of COVID-19, including 6,384,128 deaths, reported to WHO. As of 26 July 2022, a total of 12,248,795,623 vaccine doses have been administered.
Global and regional HIV epidemic, 2021

New infection every two minutes in AGYW 2021

- Eastern Europe and central Asia, Latin America, and the Middle East and North Africa have all seen increases in annual HIV infections over several years
- New HIV infections are rising where they had been falling
- New infections dropped only 3.6% between 2020 and 2021, the smallest annual decline since 2016
Decline in number of people acquiring HIV and HIV-related deaths globally over time

- Decline in number of new HIV infections has stagnated.
- Will miss the 2025 target unless treatment coverage is accelerated and effective prevention efforts re-invigorated and barriers to inclusion are removed.

2021 new HIV infections
1,500,000 [1,100,000–2,000,000]

2021 AIDS-related deaths
650,000 [510,000–860,000]

Source: UNAIDS/WHO estimates
Distribution of acquisition of new HIV infections by population, global, 2021

- 12% Sex workers
- 30% Remaining population
- 25% Clients of sex workers and sex partners of other key populations
- 21% Gay men and other men who have sex with men
- 10% People who inject drugs
- 2% Transgender women

Source: UNAIDS special analysis, 2022
HIV service cascade, global, 2021

95-95-95 targets by 2030

- 95 percent of people living with HIV know their status
- 95 percent of people living with HIV who know their status are receiving treatment
- 95 percent of people on treatment have suppressed viral loads
- Number of people on HIV treatment grew more slowly in 2021 than it has in over a decade

The denominator is the value from the previous bar in the last three bars. For example, 88% of people who were aware of their status were receiving ART.
Progress towards 90–90–90 and 95–95–95 targets of the HIV service cascade, by WHO region, 2021

Source: UNAIDS/WHO estimates
Percentage of countries reporting disruptions in communicable disease (TB, HIV, hepatitis and malaria) services during the COVID-19 pandemic in Q4 2021

### About half of countries report disruptions HIV testing and prevention services, and hepatitis B & C diagnosis and treatment

<table>
<thead>
<tr>
<th>Service</th>
<th>Countries Reporting Disruptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB diagnosis and treatment (n=90)</td>
<td>31% (5-25%), 16% (26-50%), 2% (more than 50%)</td>
</tr>
<tr>
<td>HIV testing services (n=87)</td>
<td>31% (5-25%), 14% (26-50%), 5% (more than 50%)</td>
</tr>
<tr>
<td>Hepatitis B and C diagnosis and treatment (n=62)</td>
<td>24% (5-25%), 19% (26-50%), 5% (more than 50%)</td>
</tr>
<tr>
<td>HIV prevention services (n=82)</td>
<td>30% (5-25%), 13% (26-50%), 4% (more than 50%)</td>
</tr>
<tr>
<td>Malaria surveillance (n=53)</td>
<td>26% (5-25%), 4% (26-50%), 8% (more than 50%)</td>
</tr>
<tr>
<td>Insecticide-treated-mosquito nets (n=45)</td>
<td>20% (5-25%), 7% (26-50%), 9% (more than 50%)</td>
</tr>
<tr>
<td>Initiation of new ARV treatment (n=83)</td>
<td>24% (5-25%), 6% (26-50%), 1% (more than 50%)</td>
</tr>
<tr>
<td>Seasonal malaria chemoprevention (n=10)</td>
<td>10% (5-25%), 10% (26-50%), 10% (more than 50%)</td>
</tr>
<tr>
<td>Malaria diagnosis and treatment (n=52)</td>
<td>19% (5-25%), 4% (26-50%), 4% (more than 50%)</td>
</tr>
<tr>
<td>Indoor residual spraying (n=40)</td>
<td>15% (5-25%), 0% (26-50%), 8% (more than 50%)</td>
</tr>
<tr>
<td>Continuation of established ARV treatment (n=84)</td>
<td>14% (5-25%), 5% (26-50%), 20% (more than 50%)</td>
</tr>
</tbody>
</table>

Source: Round 3 Global pulse survey on continuity of essential health services, Nov-Dec 2021 (reflecting situation during previous 6 months)
Perceptions of levels of disruption and recovery in communicable disease services during the COVID-19 pandemic in Q4 2021 as compared to Q1 2021

### About half of countries report disruptions HIV testing and prevention services, and hepatitis B & C diagnosis and treatment

<table>
<thead>
<tr>
<th>Service</th>
<th>Countries Back to pre-pandemic levels (%)</th>
<th>Countries Still disrupted, better than Jan-March 2021 (%)</th>
<th>Countries Still disrupted, no change from Jan-March 2021 (%)</th>
<th>Countries Still disrupted, worse than Jan-March 2021 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seasonal malaria chemoprevention (n=9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation of established ARV treatment (n=80)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation of new ARV treatment (n=83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV prevention services (n=82)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insecticide-treated-mosquito nets (n=45)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria diagnosis and treatment (n=52)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B and C diagnosis and treatment (n=61)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indoor residual spraying (n=39)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria surveillance (n=53)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV testing services (n=86)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB diagnosis and treatment (n=90)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Round 3 Global pulse survey on continuity of essential health services, Nov-Dec 2021 (reflecting situation during previous 6 months)
HIV and COVID-19 mortality: a review of systematic reviews and meta-analysis

- 8/13 reviews reported an increased risk of COVID-19 mortality in PLWHIV (ranging from 19% to 129%)
- 5/13 reported similar mortality risk
- No review showed a reduced risk among PLWHIV

References: Wang Y et al; Han X et al; Hariyanto T; Wang Y et al; Ssentongo P et al; Oyelade T et al; Moradi Y et al; Dong Y et al; Dzinamara T et al; Liang M et al; Danwang C et al; Sarkar S et al; Ssentongo P et al.
COVID-19 mortality over time by HIV status

Emerging COVID-19 variants

Alpha, Beta, Epsilon, Kappa, Delta, Iota, Gamma, Lambda, Eta

Theta, Zeta, Mu

Omicron

Analyses based only on data from South Africa N=311,000
(2020=105,603, 2021=185,951, 2022=19,446)

Bertagnolio S, et al.
National policy on HIV self-testing and implementation status, July 2022

By July 2022, 98 countries adopted HIV self-testing policies in their national guidelines, with 52 countries routinely implemented the policy.
By July 2022, 108 countries (88%) adopting DTG as part of the preferred first-line antiretroviral therapy for adults and adolescents, an 80% increase from 60 countries in 2020 when data for this indicator was first collected.
Adoption of DTG regimens as the preferred treatment option in national guidelines for all infants and children living with HIV, July 2022

By July 2022, DTG has been adopted as the preferred treatment initiation option for infants and children in 55% (60/110) of reporting countries, this represents a 71% increase from 2020, when adoption of DTG as the preferred treatment initiation option was reported by 35 countries.

Source: Global AIDS Monitoring (UNAIDS/WHO/UNICEF) and Global HIV, Hepatitis and STIs Programmes (HHS), WHO, 2022

Disclaimer: The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
By July 2022, routine viral load monitoring for adults and adolescents has been implemented countrywide in 74% (91/123) of reporting low- and middle-income countries; of the remainder almost half (47%, 15/32) reported implementation in many (50–95%) treatment sites.
Overall impact of a guideline change: significant improvements to the VLS

- Transition to TLD was followed by near universal improvements in viral load suppression
- Due to better tolerance/adhesion? Getting rid of NNRTI resistance issues? Combination?
- Early adopters (such as Nigeria, Haiti, and DRC) are still seeing population-level improvements in BSSs
- Slightly flatter curves for the countries furthest behind in adopting TLDs
Globally, majority of countries have partially adopted at least 1 DSD model in their national policies, by end 2021.
National policies on frequency of ART pick-up for people who are stable on ART, 2021

National policies on frequency of ART pick-up for people who are stable on ART, 2021 (n = 146 reporting countries)

- No policy, 18 (12%)
- Policy, 128 (88%)

Frequency of ART pick-up for people who are stable on ART, by WHO region, 2021 (n = 128 reporting countries)

- African Region (n = 43)
- Region of the Americas (n = 28)
- South-East Asia Region (n = 10)
- European Region (n = 16)
- Eastern Mediterranean Region (n = 16)
- Western Pacific Region (n = 15)

Source: Global AIDS Monitoring (UNAIDS/WHO/UNICEF) and Global HIV, Hepatitis and STIs Programmes (HHS), WHO, 2021
WHO Operational guidance for maintaining HIV services in the COVID-19 context

- Emphasize same-day start for ART including starting outside of a facility (e.g. during outreach or when attending mobile services).
- Extend to 6-monthly dispensing
- Promote and scale-up of models of ART dispensing outside the facility (community)

Countries make pivotal changes to maintain HIV services during the COVID-19 pandemic and these will likely build long-term benefits

- Resilient responses includes:
  - DSD models and multi-month provision of meds, community pickup, use of ehealth and mhealth technology, & strong community engagement
  - Expanding eligibility and transitioning from 3 to 6 months supply when possible
  - Embracing out of facility (community) models,
  - Less frequent visits to a health facility with less frequent medication pick-ups,
  - Integrating/aligning ART refills with other health services (preventive and chronic medications such as TB, TPT, AHD, NCDs, FP)
  - Virtual Case Management
  - Improved focus on people-centered care

Links:
- https://www.who.int/publications-detail/10665-332240
Reduction in testing and ART initiation during C19

ANC – HIV Testing at First ANC Visit

Adult: ART initiation (naïve)

Total ART initiations Apr -> Dec
- 2018: 482,472
- 2019: 529,743
- 2020: 343,368

Adult Naïve ART initiation – vs January 20
Change in PEPFAR HIV testing strategy

Transitioning from a wide-scale HIV testing services to more targeted testing – 35% reduction in PEPFAR testing volume targets between 2018 & 2020

Source: PEPFAR Panorama Spotlight, 2021
• Focus on maintaining access to treatment and care
  • MMD, pharmacy/community pick up, home delivery, keeping PHC open, virtual and digital platforms for remote support and appropriate PPE for health workers

• But need to also try and maintain testing services
  • avoid losing substantial HIV, STI and Hepatitis gains
  • support people with who are undiagnosed or unlinked to treatment
  • Maintain prevention services for those at high ongoing risk

*Some reports highlighted COVID-19 affecting HIV testing services – w/ HIV testing volumes and total positive diagnoses

HIV testing uptake

Planning needed to avoid stockouts

COVID-19 disruptions in all regions, especially key populations

Retrospective analysis comparing 2019 and 2020 data, from 44 countries, showed:

- **35.4% reduction in testing** (45% in LAC, 39% in Asia, 35% in Africa and 26% in Europe.)

- **9.5% increase in HIV positivity** (44% in Europe, 19% in LAC, 14% in Asia and 2% in Africa)

- Key and vulnerable populations received substantially fewer tests than before, especially SW, TG, MSM and migrants.

- Trends illustrate targeted testing strategies used increasingly during COVID-19

- Catch-up strategies may be needed for some settings and populations missed, especially key and vulnerable populations.

<table>
<thead>
<tr>
<th>Population</th>
<th>% Reduction in tests HIV tests</th>
<th>% Increase in HIV positive tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSM</td>
<td>41.82 (41.58-42.06)</td>
<td>2.92 (1.74-4.58)</td>
</tr>
<tr>
<td>TG</td>
<td>52.85 (51.60-54.10)</td>
<td>33.37 (30.09-36.78)</td>
</tr>
<tr>
<td>SW</td>
<td><strong>58.75 (58.38-59.12)</strong></td>
<td>24.14 (19.54-29.22)</td>
</tr>
<tr>
<td>PWID</td>
<td>10.74 (10.43-11.05)</td>
<td>49.04 (45.07-53.03)</td>
</tr>
<tr>
<td><strong>Migrants</strong></td>
<td>41.3 (41.04-41.58)</td>
<td><strong>63.07 (55.48-70.21)</strong></td>
</tr>
<tr>
<td>People in prison</td>
<td>0 (slight increase reported)</td>
<td>0 (slight decrease reported)</td>
</tr>
</tbody>
</table>

WHO HTS and ART initiation adaptations for COVID-19

Key considerations

1. Prepare a **strategy for HTS adaptation** gradual and proportional COVID-19 community circulation and health system disruptions
2. Protect and support **frontline HIV providers**: IPC training, access to PPE, and COVID-19 care and vaccine
3. **Prioritization of HTS:**
   - Individuals suspected of **advanced HIV disease**
   - Individuals suspected or **diagnosed with TB, STI, malnutrition**
   - ANC, including retesting, as well as **early infant diagnosis (EID)**
4. **ART initiation** should be offered on the **same day** as HIV testing to people who are ready to start and different DSD models available to ensure access
5. **Scale-up HIV self-testing (HIVST) especially outside of facilities**, including PEP/PrEP
6. HTS with higher HIV positivity, e.g., index testing, should be prioritized
7. Maintain services for **key population** using **virtual interventions** (outreach and follow-up; information on COVID-19; tracing; virtual consultations and referrals)
8. **Greater integration** and explore potential **synergy between COVID-19 & HTS**: simultaneous testing (e.g. integrate HTS/HIVST with mask distribution, vaccinations in high HIV burden settings)
9. Mitigate impact of COVID-19 on demand side factors: **Promote** use of services; **protect** patients; ensure **access** to essential services
10. Data **monitoring** and operational **research**: report and scale-up initiatives
**HIVST in the COVID-19 context**

**Key considerations for HIVST**

- **HIVST can be used** to maintain services while adhering to physical distancing guidance.
- Important to strategically implement HIVST **prioritizing areas & populations** with greatest needs and gaps in testing coverage.
- **HIVST approaches include:**
  - distribution for personal use and/or sexual and/or drug injecting partners of PLHIV and social contacts of key populations
  - in high HIV burden settings, pregnant women may also provide HIVST kits to their male partners.
- **Priority settings to consider:**
  - pick up at facilities or community sites
  - virtual platforms (e.g., websites and social media) and distribution through mail
  - pharmacies, retail vendors, vending machines
  - linked to PrEP and PEP programmes

**Countries with HIVST programmes**

- Replace facility with HIVST (to decongest health facilities)
- Expand and adapt HIVST
- Use HIVST for partner services, workplace and social network testing
- HIVST for maintaining PrEP/PEP services

**Countries yet to offer HIVST**

- Lobby for rapid HIVST approval, registration and use
- Select HIVST products Start procurement
- Start pilot or full implementation in priority populations and geographies

$1 HIV self-test kit increasing access

- 98 countries with HIVST policies & >10 million HIVST kits procured in LMIC annually
  - Yet only 52 countries implementing HIVST with an estimated unmet need of 180 million tests per year
- WHO has now prequalified 6 HIV self-tests, with this new $1 option in 140 countries more countries will be able to implement
  - MedAccess estimates over next 5 years 8.1 million people will use the test, closing gaps in HIV testing, treatment and prevention
- Cost barriers have been an issue hindering wide-scale implementation in many settings
  - Expanding existing uses for case finding, as well as new opportunities for prevention programmes, broader health system efficiencies and integration efforts (such as in family planning and SRH services)

Source: WHO 2022, Devex 2022
Studies show the feasibility of introducing innovative approaches for testing, PrEP and ART, OST and other treatment distribution as possible and important solutions in LMIC settings during COVID-19.

- **PrEP/ART teleconsultation**
  - In Brazil, PrEP teleconsultation was experienced by 23% of users, with 89% feeling satisfied and 70% reporting high openness and acceptability to PrEP teleconsultation. (Q2 #1)
  - In Italy, 24% of patients in a large HIV clinic used teleconsulting, with no patients visiting the unit presented with acute COVID. (Q2 #5)
  - In Australia, HIV care continued with 95% and 98% being able to access their HIV provider and antiretroviral therapy (ART), respectively. **Telehealth was used by 92% and was largely well received.** (Q2 #14)

- **Multi-month dispensing:** In Egypt, multi-month dispensing of ART was implemented among a small group of participants (n=40) who **self-reported increased adherence.** (Q2#2)

- **Telemedicine Pre-Planning:** In a randomized trial of visits delivered by telemedicine in the US, HIV patients were randomized to have a pre-visit planning call to address barriers to telemedicine visit versus a standard reminder call. **No difference between pre-visit and control in scheduled visit attendance (83% v. 78%, OR 1.38, 95% CI 0.67–2.81).** (Q2#3)
Country examples and innovations from EPIC Program

**Eswatini: Community distribution model**

- Eswatini government-initiated model in response to COVID-19
- Community sites: drug shops, closed schools, churches, etc.
- Distributes ARVs, TB, and NCD medications (antidiabetic, antihypertensives) FP products, PrEP, and condoms
- Targets populations extend beyond ART clients.

**Lesotho: Automated dispensing model: BonoloMeds**

- 215 Clients have enrolled in the e-locker model
- 46 Clients have so far successfully picked up their ARV refills from the e-lockers. Others are scheduled for later pick-up dates.

**Indonesia: Ride-based app and courier service home delivery**

- Health facility staff contacted the client to confirm address and desire for ARV home delivery.
- Medication is packed in containers concealing the contents and sent to the client through the Jak-Anter delivery system via a ride-based app or transport courier service such as Tiki, JNE, Grab, or Gojek.
- Facilities first pay the transportation fees and then are reimbursed by USAID/LINKAGES.

Source: FHI360 EPIC
Virtual Interventions - Rapid COVID 19 response

• Mitigate the impact of COVID 19 on programmes
• **Self – care** option of accessing services
• **Decongest the facilities** to avoid infection related risks
• **Home delivery of HIV ST kits, ART, PrEP** for self and partners
• Can be adapted for all populations and services
• **Real time tracking and data management**
Virtual Case Management as a response to COVID 19

- Physical vs virtual outreach during COVID 19 lockdowns in Nepal
- Use of social media platforms and dating apps to reach new populations online
- Use of digital social content on prevention and treatment;
- Peer champions, case management teams, and community-based supporters delivered ART directly to clients’ homes
- Case management support for 75% PLHIV shifted online

Source: FHI360 Nepal
New section on monitoring DSD in 2022 WHO SI guidelines

WHO 2022 Five key recommendations for the patient monitoring system
1. Analyse and use routine testing data to optimise HIV testing services
2. Use person-centred patient data to assess ART interruption, improve re-engagement and retention in care
3. Integrate the monitoring of DSD within the HIV patient monitoring system
4. Enhance data quality and use
5. Use drug stock data

Differentiated service delivery

✓ 5 new indicators for monitoring DSD implementation and outcomes
  ✓ DSD 1. Multi month ARV dispensation
  ✓ Example tools and country case study
  ✓ Minimum data elements for monitoring DSD
  ✓ Update of patient monitoring tools for tracing DSD interventions and monitoring retention and health outcomes
  ✓ Update of patient monitoring tools, ART cohort and cross-sectional reports to enable monitoring of DSD
WHO at AIDS 2022
Thank you

For more information, please contact:

Global HIV, Hepatitis and Sexually Transmitted Infections Programmes
E-mail: hiv-aids@who.int
www.who.int/health-topics/hepatitis